C4 Therapeutics, Inc. Interest and Other Income
C4 Therapeutics, Inc. (CCCC) reported Interest and Other Income of $2.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-11
- C4 Therapeutics, Inc. interest and other income for the quarter ending 2026-06-30 was $2.79M, a 12.37% increase year-over-year.
- C4 Therapeutics, Inc. interest and other income for the quarter ending 2026-03-31 was $2.66M, a 6.54% decline year-over-year.
- C4 Therapeutics, Inc. interest and other income for the quarter ending 2025-12-31 was $2.78M, a 14.91% decline year-over-year.
- C4 Therapeutics, Inc. interest and other income for the quarter ending 2025-09-30 was $2.25M, a 37.23% decline year-over-year.
- C4 Therapeutics, Inc. interest and other income for fiscal 2025 was $10.35M, a 28.28% decline from fiscal 2024.
- C4 Therapeutics, Inc. interest and other income for fiscal 2024 was $14.43M, a 47.05% increase from fiscal 2023.
- C4 Therapeutics, Inc. interest and other income for fiscal 2023 was $9.81M, a 174.46% increase from fiscal 2022.
- C4 Therapeutics, Inc. interest and other income for fiscal 2022 was $3.58M, a 823.77% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.79M 10-Q · filed 2026-08-11 | $5.44M 10-Q · filed 2026-08-11 | $8.22M derived: sum of 3 quarters · filed 2026-08-11 | $10.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.66M 10-Q · filed 2026-05-12 | $5.44M derived: sum of 2 quarters · filed 2026-05-12 | $7.68M derived: sum of 3 quarters · filed 2026-05-12 | $10.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.03M derived: sum of 2 quarters · filed 2026-02-26 | $7.51M derived: sum of 3 quarters · filed 2026-08-11 | $10.35M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.25M 10-Q · filed 2025-11-06 | $4.73M derived: sum of 2 quarters · filed 2026-08-11 | $7.57M 10-Q · filed 2025-11-06 | $10.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.48M 10-Q · filed 2026-08-11 | $5.32M 10-Q · filed 2026-08-11 | $8.59M derived: sum of 3 quarters · filed 2026-08-11 | $12.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.84M 10-Q · filed 2026-05-12 | $6.11M derived: sum of 2 quarters · filed 2026-05-12 | $9.69M derived: sum of 3 quarters · filed 2026-05-12 | $13.41M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.84M derived: sum of 2 quarters · filed 2026-02-26 | $10.57M derived: sum of 3 quarters · filed 2026-02-26 | $14.43M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.58M 10-Q · filed 2025-11-06 | $7.30M derived: sum of 2 quarters · filed 2025-11-06 | $11.16M 10-Q · filed 2025-11-06 | $14.11M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.73M 10-Q · filed 2025-08-07 | $7.58M 10-Q · filed 2025-08-07 | $10.53M derived: sum of 3 quarters · filed 2025-08-07 | $13.10M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.86M 10-Q · filed 2025-05-07 | $6.81M derived: sum of 2 quarters · filed 2025-05-07 | $9.37M derived: sum of 3 quarters · filed 2025-05-07 | $11.62M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.51M derived: sum of 2 quarters · filed 2025-02-27 | $7.76M derived: sum of 3 quarters · filed 2025-02-27 | $9.81M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.56M 10-Q · filed 2024-10-31 | $4.81M derived: sum of 2 quarters · filed 2024-10-31 | $6.86M 10-Q · filed 2024-10-31 | $8.57M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $2.25M 10-Q · filed 2024-08-01 | $4.30M 10-Q · filed 2024-08-01 | $6.01M derived: sum of 3 quarters · filed 2024-08-01 | $7.09M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $2.05M 10-Q · filed 2024-05-08 | $3.76M derived: sum of 2 quarters · filed 2024-05-08 | $4.85M derived: sum of 3 quarters · filed 2024-05-08 | $5.35M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.79M derived: sum of 2 quarters · filed 2024-02-22 | $3.30M derived: sum of 3 quarters · filed 2024-02-22 | $3.58M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.08M 10-Q · filed 2023-11-01 | $1.59M derived: sum of 2 quarters · filed 2023-11-01 | $1.87M 10-Q · filed 2023-11-01 | $2.00M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $506.00K 10-Q · filed 2023-08-08 | $782.00K 10-Q · filed 2023-08-08 | $918.00K derived: sum of 3 quarters · filed 2023-08-08 | $1.03M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $276.00K 10-Q · filed 2023-05-04 | $412.00K derived: sum of 2 quarters · filed 2023-05-04 | $522.00K derived: sum of 3 quarters · filed 2023-05-04 | $591.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $246.00K derived: sum of 2 quarters · filed 2023-02-23 | $315.00K derived: sum of 3 quarters · filed 2023-02-23 | $387.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $110.00K 10-Q · filed 2022-11-03 | $179.00K derived: sum of 2 quarters · filed 2022-11-03 | $251.00K 10-Q · filed 2022-11-03 | $310.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $69.00K 10-Q · filed 2022-08-04 | $141.00K 10-Q · filed 2022-08-04 | $200.00K derived: sum of 3 quarters · filed 2022-08-04 | $250.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $72.00K 10-Q · filed 2022-05-05 | $131.00K derived: sum of 2 quarters · filed 2022-05-05 | $181.00K derived: sum of 3 quarters · filed 2022-05-05 | $206.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $109.00K derived: sum of 2 quarters · filed 2022-02-24 | $134.00K derived: sum of 3 quarters · filed 2022-02-24 | $393.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $50.00K 10-Q · filed 2021-11-10 | $75.00K derived: sum of 2 quarters · filed 2021-11-10 | $334.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $25.00K 10-Q · filed 2021-08-11 | $284.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $259.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $2.16M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |